JP2018503644A5 - - Google Patents

Download PDF

Info

Publication number
JP2018503644A5
JP2018503644A5 JP2017537500A JP2017537500A JP2018503644A5 JP 2018503644 A5 JP2018503644 A5 JP 2018503644A5 JP 2017537500 A JP2017537500 A JP 2017537500A JP 2017537500 A JP2017537500 A JP 2017537500A JP 2018503644 A5 JP2018503644 A5 JP 2018503644A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
patient
treatment
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017537500A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018503644A (ja
JP7274258B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2016/050804 external-priority patent/WO2016113404A1/en
Publication of JP2018503644A publication Critical patent/JP2018503644A/ja
Publication of JP2018503644A5 publication Critical patent/JP2018503644A5/ja
Application granted granted Critical
Publication of JP7274258B2 publication Critical patent/JP7274258B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017537500A 2015-01-16 2016-01-15 リキシセナチドを用いた小児2型真性糖尿病患者の治療 Active JP7274258B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15151488.2 2015-01-16
EP15151488 2015-01-16
PCT/EP2016/050804 WO2016113404A1 (en) 2015-01-16 2016-01-15 Treatment of pediatric type 2 diabetes mellitus patients with lixisenatide

Publications (3)

Publication Number Publication Date
JP2018503644A JP2018503644A (ja) 2018-02-08
JP2018503644A5 true JP2018503644A5 (enExample) 2019-02-14
JP7274258B2 JP7274258B2 (ja) 2023-05-16

Family

ID=52354814

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017537500A Active JP7274258B2 (ja) 2015-01-16 2016-01-15 リキシセナチドを用いた小児2型真性糖尿病患者の治療

Country Status (21)

Country Link
US (4) US20160235818A1 (enExample)
EP (1) EP3244912B1 (enExample)
JP (1) JP7274258B2 (enExample)
KR (1) KR102614574B1 (enExample)
CN (1) CN107405386A (enExample)
AR (1) AR103415A1 (enExample)
AU (1) AU2016207964B2 (enExample)
CL (1) CL2017001843A1 (enExample)
CR (1) CR20170376A (enExample)
EA (1) EA035423B1 (enExample)
ES (1) ES2895513T3 (enExample)
IL (1) IL253460B (enExample)
MX (1) MX381944B (enExample)
PH (1) PH12017501290A1 (enExample)
PL (1) PL3244912T3 (enExample)
PT (1) PT3244912T (enExample)
SG (1) SG11201705755UA (enExample)
TN (1) TN2017000292A1 (enExample)
TW (1) TWI706779B (enExample)
WO (1) WO2016113404A1 (enExample)
ZA (1) ZA201704512B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3228320T (pt) 2008-10-17 2020-03-26 Sanofi Aventis Deutschland Combinação de uma insulina e de um agonista do glp-1
SG10201500871TA (en) 2009-11-13 2015-04-29 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist and methionine
CN107206058A (zh) 2014-12-12 2017-09-26 赛诺菲-安万特德国有限公司 甘精胰岛素/利西拉来固定比率配制剂
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第2型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第2型糖尿病病患之治療
DE102019129444A1 (de) * 2019-10-31 2021-05-06 Lts Lohmann Therapie-Systeme Ag Lagtime-Verkürzung/Eisspray
US20240201166A1 (en) * 2021-04-11 2024-06-20 Vikas Khurana Diagnosis and treatment of congestive colon failure (ccf)
WO2024133412A1 (en) 2022-12-21 2024-06-27 Novo Nordisk A/S Methods and systems for estimating fbg value from cgm data

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
AR075204A1 (es) * 2009-01-29 2011-03-16 Boehringer Ingelheim Int Inhibidores de dpp-4 y composiciones farmaceuticas que los comprenden, utiles para tratar enfermedades metabolicas en pacientes pediatricos, particularmente diabetes mellitus tipo 2
US20120231022A1 (en) * 2009-05-28 2012-09-13 Amylin Pharmaceuticals, Inc. Glp-1 receptor agonist compounds for sleep enhancement
SI2324853T1 (sl) * 2009-11-13 2015-12-31 Sanofi-Aventis Deutschland Gmbh Liksisenatid kot dodatek metforminu pri zdravljenju sladkorne bolezni tipa 2
EP2707017B1 (en) * 2011-05-13 2015-09-16 Sanofi-Aventis Deutschland GmbH Lixisenatide and metformin for treatment of diabetes type 2
US9821032B2 (en) * 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
WO2013003449A2 (en) * 2011-06-27 2013-01-03 Phasebio Pharmaceuticals, Inc. Methods of treatment with glp-1 receptor agonists
JP6367115B2 (ja) * 2011-08-29 2018-08-01 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 2型糖尿病患者の血糖コントロールに使用する組合せ医薬
SG11201401175SA (en) * 2011-10-28 2014-09-26 Sanofi Aventis Deutschland Treatment protocol of diabetes type 2

Similar Documents

Publication Publication Date Title
HRP20161620T1 (hr) Uporaba ave0010 za proizvodnju lijeka za liječenje dijabetes melitusa tip 2
JP2017538705A5 (enExample)
RU2014111821A (ru) Фармацевтическая комбинация для применения при гликемическом контроле у пациентов с сахарным диабетом 2 типа
RU2013155474A (ru) Ликсисенатид и метформин для лечения диабета типа 2
RU2013155473A (ru) Фармацевтическая комбинация для применения для индуцирования потери массы тела у субъектов с диабетом 2 типа или/и для предотвращения набора массы тела у субъектов с диабетом 2 типа
JP2014528901A5 (enExample)
JP2014528474A5 (enExample)
RU2013155480A (ru) Фармацевтическая комбинация для применения в лечении пациентов с диабетом 2 типа
JP2013541576A5 (enExample)
JP6438944B2 (ja) インスリングラルギン/リキシセナチド固定比率製剤
RU2015134581A (ru) Доноры нитроксила с улучшенным терапевтическим индексом
JP2018509419A5 (enExample)
MX2020001342A (es) Uso de gaboxadol en el tratamiento contra diabetes y afecciones relacionadas.
JP2017014206A5 (enExample)
WO2018005801A3 (en) Novel non-systemic tgr5 agonists
WO2018005794A3 (en) Novel non-systemic tgr5 agonists
JP2020536121A5 (enExample)
JP2014513121A5 (enExample)
Alhomoud et al. Repurposing incretin therapies: a narrative review of emerging indications across cardiometabolic, liver, kidney, neurological, psychiatric, and other systems
JP2014129405A5 (enExample)
JP2011105610A5 (enExample)
Gray et al. Late positive flecainide challenge test for Brugada syndrome
RU2014150946A (ru) Способ снижения веса
WO2010132562A3 (en) Transdermal delivery of metformin
JP2008189679A5 (enExample)